Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 1.14B |
| Revenue (ttm) | 15.05M |
| Net Income (ttm) | -75.42M |
| Shares Out | 35.65M |
| EPS (ttm) | -3.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $29.25 |
| Previous Close | $31.15 |
| Change ($) | -1.90 |
| Change (%) | -6.10% |
| Day's Open | 31.25 |
| Day's Range | 28.50 - 32.00 |
| Day's Volume | 218,091 |
| 52-Week Range | 19.43 - 43.92 |
- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics fo...
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...
- PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies ...
PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel ther...
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.
There's a chance that it could become an even bigger success story.
SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...
Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.
Investors are excited about the biotech's prospects, but the company still has a long road ahead.
Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.
About PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also deve... [Read more...]
| Industry Biotechnology | IPO Date Jun 3, 2020 |
| CEO Bernard Coulie | Employees 78 |
| Stock Exchange NASDAQ | Ticker Symbol PLRX |
Financial Performance
In 2020, PLRX's revenue was $41.82 million, a decrease of -26.70% compared to the previous year's $57.05 million. Losses were -$41.53 million, 6,482.1% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 51.50, which is an increase of 76.07% from the latest price.